$XBI $110.34 -2.7%%
Covid Updates
$AXLA +0.4% Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial source
Pipeline Updates
$LYEL -0.6% Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors source
$PRTK +5.4% China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections source
$KURA +0.2% Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma source
$FBIO -5.7% Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV source
$RUBY -4.6% Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day source
$ARCT +21.1% Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials source
$NKTX -1.1% NKARTA RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR NKX101 FOR TREATMENT OF PATIENTS WITH AML source
$APTX -5.5% Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder source
$EBS +1.0% Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate source
$PRQR -0.7% ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa source
$QURE +29.6% uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease source
$INAB +1.6% IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant source
$APLT -8.5% Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency source
$KYMR -10.0% Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day source
$CGEM -3.6% Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients source
$IPSC +3.3% Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates source
$AMER Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis source
$KOD -2.3% Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion source
Business Updates
$ABEO -6.4% Abeona Therapeutics Announces Public Offering of Common Stock and Warrants source
$LEGN +2.5% Legend Biotech Corporation Announces Pricing of Public Offering source
Posted by JM
Comentarios